Estrera, Cleazy B.
HRN: 22-15-80 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/24/2022
CO-AMOXICLAV 625MG (TAB)
11/24/2022
12/01/2022
PO
625mg
Bid
RMLE And Repair
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes